While interest in the psychedelic drug development business is beginning to pick up, one Australia-based advocate said it’s still very early in the country.

In an interview with the Investing News Network (INN) Peter Hunt, chairman of Mind Medicine Australia, shared his expectations for the development of the psychedelics industry in Australia as the sector begins to accelerate in North America.


Mind Medicine Australia, which is not related to the Canadian psychedelics firm Mind Medicine (NEO:MMED), is a research and advocacy non-profit group looking to expand the conversation surrounding this alternative drug opportunity.

Hunt knows a thing or two about investment opportunities having retired in 2018 from a 37 year career in investment banking with Greenhill, which he co-founded.

“We’re all about developing the ecosystem down here so that these medicines can become available to Australians who need them. Irrespective of the wealth of the Australian, savings or whatnot, we want them to be broadly available through the medical system,” he said.

Treating mental health conditions with psychedelics

Hunt is passionate about the opportunity psychedelic medicines offer in treating various mental health conditions, such as depression, anxiety and post-traumatic stress disorder.

Speaking recently at an online seminar designed to give investors a sense of the opportunity attached to psychedelics, Hunt said one in five Australian adults currently faces a chronic mental health illness, representing approximately 4.8 million people.

Hunt told INN he has not seen attacks against the psychedelic drug industry, which has greatly surprised him. Overall, there is much enthusiasm surrounding the potential of these drugs and the investment opportunity attached to the industry.

However, he has seen trepidation attached to a need for more data.

“We always need more research, but the problem is, when you’ve got lots of people suffering … you can keep doing research, but at some stage, you’ve got to say … let’s just start using (psychedelic medicines) in a safe environment with safe protocols and try and help people,” Hunt said.

Australian psychedelics market still young

When it comes to the investment landscape in the Australian psychedelics market compared to the space in Canada, Hunt said Australia still has a long way to go.

“It really is early days, and I think investors are just trying to understand the facts and the data,” he said.

When asked about the potential for a public listing of a psychedelics company in the Australian market, Hunt said it could very well happen before the end of the year.

“It’s probably going to be later this year, or sometime next year,” he said to INN. “I think it’s definitely going to happen.”

Roadblocks attached to research will see a shot in validity once a larger institution, such as a university, becomes a partner attached to a study with these medicines, Hunt said.

While he couldn’t confirm specific details at the time, Hunt said there are advanced discussions between his group and an Australian university to set up an official research partnership, which he said would be a huge boost for the growth of the sector in the country.

“Universities extend knowledge, and I think we’re just touching the surface in terms of just how powerful psychedelic medicine can be across a whole range of mental illnesses,” he said.

Don’t forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today its participation in the following investor conferences:

  • Needham 2nd Annual Virtual Cannabis Conference – March 3 rd , 2021 – Management will participate in virtual one-on-one meetings.
  • 33rd Annual Roth Conference – March 15 th -17 th , 2021 – Charlie Bachtell, CEO and Co-Founder, will participate in a Fireside Chat and management will later participate in virtual one-on-one meetings on April 7 th .
  • Stifel Multi-Sector Conference – April 21 st , 2021 – Management will participate in virtual one-on-one meetings.

About Cresco Labs

Keep reading... Show less

Green Thumb Industries, a leading cannabis consumer packaged goods company and owner of Rise™ Dispensaries, is expanding key partnerships and creating scholarships earmarked for those from communities most impacted by the war on drugs as part of its corporate social responsibility program. The scholarships will be granted to a total of four students for programs at the Cleveland School of Cannabis in Ohio and Olive-Harvey College in Illinois. Additionally, Green Thumb will continue its support of Cabrini Green Legal Aid and partner with the North Lawndale Employment Network in Chicago as part of ongoing collaborations that include financial support, volunteerism and awareness initiatives.

Building on the foundation of Green Thumb’s LEAP initiative, which provided pro-bono support for social equity license applicants in Illinois and which will soon offer business incubator resources to newly awarded social equity entrepreneurs, these impactful partnerships mark a critical next step in prioritizing diversity, equity, and inclusion in the cannabis industry.

Keep reading... Show less

All five flavours of the Company’s KOIOS™ nootropic beverage product are now being carried by Jensen’s, a regional supermarket chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. This placement of KOIOS™ follows several other recent placements of the Company’s beverage products in regional supermarket chains across the United States as part of a strategy to passively build market share in specific geographical areas.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that the full range of five flavours of its KOIOS ™ nootropic beverages can now be purchased at all grocery stores operated by Jensen’s Foods (“Jensen’s”), a long-established family-owned grocery chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. In a press release dated February 19, 2021 the Company announced another chain-wide placement of KOIOS ™ nootropic beverages on the west coast of the United States with Market of Choice in Oregon. With this placement of KOIOS ™ in Jensen’s supermarkets, the Company’s beverage products are now carried in approximately 180 retail stores on the west coast, out of a total of more than 4,000 retail stores nationwide.

Keep reading... Show less

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at “The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference”, a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.

As a presenting sponsor, the Company will connect directly with some of the earliest moving investors in the psychedelic industry and reach an audience of 2,000+ investors. Presentations are 30 minutes in length, with 10 minutes allocated to a one-on-one Q&A session with the audience.

Keep reading... Show less

As Canadian operators race to strengthen their positions in the cannabis landscape, are international pursuits outside North America still top of mind?

The role that mergers and acquisitions (M&A) have played in the expansion of Canadian companies across the globe has been monumental for the growth of the cannabis industry. Now the space has reached a critical point as the demands of the US market increase.

Keep reading... Show less